

MATICA ENTERPRISES INC.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017

(Unaudited)

(Expressed in Canadian Dollars)

NOTICE TO READER

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the condensed interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed interim financial statements have been prepared by and are the responsibility of management.

The Company's independent auditor has not performed a review of these financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

MATICA ENTERPRISES INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (Unaudited) (Expressed in Canadian Dollars)

	Notes	September 30, 2018	December 31, 2017
			(Audited)
		\$	\$
ASSETS			
Current Assets			
Cash and cash equivalents	10	5,718,535	3,813,666
Marketable securities	4	2,625,000	1,050,000
Convertible debenture	5(a)	619,000	-
Accounts receivable		4,195	6,941
Prepaid expenses		49,338	30,885
Total current assets		9,016,068	4,901,492
Investment in RoyalMax	5(b)	5,677,970	3,805,064
Long term loans	5(c),5(d)	983,595	-
TOTAL ASSETS		15,677,633	8,706,556
LIABILITIES			
Current Liabilities			
Accounts payable and accrued liabilities		46,750	65,229
Due to related parties	8	9,037	13,719
Flow-through renunciation obligations	11	150,152	150,152
Total current liabilities		205,939	229,100
CHARFILOL DEDGLEOUITY (DEFICIENCY)			
SHAREHOLDERS' EQUITY (DEFICIENCY)	7	22 044 442	16 505 100
Share capital	1	23,844,112	16,525,123
Contributed surplus		5,705,406	3,712,574
Deficit		(14,077,824)	(11,760,241)
Total shareholders' equity (deficiency)		15,471,694	8,477,456
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)		15,677,633	8,706,556

NATURE OF BUSINESS AND GOING CONCERN (Note 1) COMMITMENTS AND CONTINGENCIES (Notes 11 and 12) SUBSEQUENT EVENTS (Note 14)

APPROVED ON BEHALF OF THE BOARD ON NOVEMBER 28, 2018:

/s/ "Boris Ziger"	
Boris Ziger, Director	
/s/ "George A. Brown"	
George A Brown Director	

MATICA ENTERPRISES INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017 (Unaudited) (Expressed in Canadian Dollars)

	Notes	Three Months Ended September 30			nths Ended mber 30	
		2018	2017	2018	2017	
		\$			\$	
GENERAL AND ADMINISTRATIVE EXPENSES						
Management and directors' fees	8	39,000	39,000	117,000	109,500	
Office and miscellaneous		12,395	8,208	55,447	19,957	
Professional fees		46,300	14,161	159,725	33,661	
Rent	12	11,067	10,215	32,150	33,044	
Share-based compensation	7(d), 8	1,037,900	1,032,900	4,164,400	1,266,400	
Transfer agent and filing fees		(1,551)	10,110	20,862	23,116	
Travel, marketing and promotion		14,858	21,204	220,855	15,042	
Total general and administrative expenses		1,159,969	1,135,798	4,770,439	1,500,720	
OTHER INCOME (EXPENSES)						
Other income		14,891	1,400	23,891	1,400	
Realized gain on marketable securities	4	-	-	-	27,600	
Unrealized gain (loss) on marketable securities	4	525,000	-	1,575,000	-	
Gain (loss) on settlement of debt		-	-	-	(309)	
Total other income (expenses)		539,891	-	1,598,891	28,691	
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)		(620,078)	(1,134,398)	(3,171,548)	(1,472,029)	
LOSS PER SHARE - BASIC AND DILUTED		(0.00)	(0.01)	(0.01)	(0.01)	

WEIGHTED AVERAGE NUMBER OF COMMON SHARES 295,116,670 <u>221,190,234</u> **289,733,693** 175,969,772

MATICA ENTERPRISES INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017 (Unaudited) (Expressed in Canadian Dollars)

		Common	shares	Contributed		Shareholders' Equity
	Notes	Shares	Amount	Surplus	Deficit	(Deficiency)
		#	\$	\$	\$	\$
Balance, December 31, 2016 Private placement units issued for cash,		139,241,691	7,460,260	294,417	(7,876,264)	(121,587)
net of issue costs		50,466,000	2,271,436	117,000	-	2,388,436
Options exercised	7(b)	22,900,000	1,115,500	(392,500)	-	723,000
Warrants exercised	7(d)	1,900,000	95,000	-	-	95,000
Shares issued for properties Units and shares issued for services and	7(b)	6,000,000	270,000	-	-	270,000
settlement of debts	7(b)	7,800,000	180,000	-	-	180,000
Share-based compensation	7(d)	-	-	1,266,500	-	1,266,500
Options cancelled/expired	7(b)	-	-	(18,941)	18,941	-
Net loss		<u> </u>	-	-	(1,472,029)	(1,472,029)
Balance, September 30, 2017		228,307,691	11,392,196	1,266,476	(9,329,352)	3,329,320
Balance, December 31, 2017 Private placement units issued for cash,		264,847,191	16,525,123	3,712,574	(11,760,241)	8,477,456
net of issue costs		1,620,000	525,000	-	-	525,000
Options exercised	7(b)	6,800,000	4,209,603	(1,317,603)	-	2,892,000
Options expired/cancelled	7(d)	-	-	(853,965)	853,965	-
Warrants exercised	7(d)	21,435,667	2,400,386	-	-	2,400,386
Shares issued for services	7(b)	648,051	184,000	-	-	184,000
Share-based compensation	7(d)	-	-	4,164,400	-	4,164,400
Net loss		-	-	-	(3,171,548)	(3,171,548)
Balance, September 30, 2018		295,350,909	23,844,112	5,207,541	(14,077,824)	15,471,694

MATICA ENTERPRISES INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017 (Unaudited) (Expressed in Canadian Dollars)

			ths Ended
		September 30,	September 30,
	Note	2018	2017
		\$	\$
OPERATING ACTIVITIES			
Net loss		(3,171,548)	(1,472,029)
Items not involving cash			
Realized (gain) on marketable securities		-	(27,600)
Unrealized (gain) loss on marketable securities		(1,575,000)	
Shares issued for property acquisition		-	270,000
Loss on settlement of debt		-	309
Share-based compensation		4,164,400	1,266,500
Shares issued for services		184,000	180,000
Olean and the second and the second telephone		(398,148)	217,180
Changes in non-cash working capital items:		0.740	40.44
Accounts receivable		2,746	10,116
Prepaid expenses		(18,453)	(70,431
Accounts payable and accrued liabilities		(18,479)	(56,003
Cash Used in Operating Activities		(432,334)	100,862
INVESTING ACTIVITIES		(242.22)	
Convertible debenture	5(a)	(619,000)	
Investment in RoyalMax	5(b)	(1,872,806)	
Secured and unsecured loans	5(c), 5(d)	(983,595)	(2.024.222
Investment in exploration and evaluation assets		-	(2,031,222
Sale of marketable securities Cash Used in Investing Activities		(3,475,501)	121,600 (1,909,622
		(3,473,301)	(1,909,022
FINANCING ACTIVITIES		E2E 000	0 200 420
Units issued for cash Exercise of options		525,000 2,892,000	2,388,436 723,000
Exercise of options Exercise of warrants		2,400,386	95,000
Due to related parties		(4,682)	16,789
Repayment of note payable		(4,002)	(10,000
Cash Provided by Financing Activities		5,812,704	3,213,225
INCREASE (DECREASE) IN CASH AND CASH		0,012,704	0,210,220
EQUIVALENTS		1,904,869	1,404,46
CASH AND CASH EQUIVALENTS, BEGINNING		3,813,666	47,154
CASH AND CASH EQUIVALENTS, ENDING		5,718,535	1,451,619
NON-CASH TRANSACTIONS:		-,, -	, ,
Shares issued for related parties debt settlement	7(b)	136,000	144,000
Shares issued for vendors debt settlement	7(b)	48,000	36,000
SUPPLEMENTAL INFORMATION:	• •	·	·
Interest paid		_	
Income taxes paid		_	

(Expressed in Canadian Dollars)

1. NATURE OF BUSINESS AND GOING CONCERN

Matica Enterprises Inc. ("Matica" or the "Company") was incorporated pursuant to the British Columbia Business Corporation Act in November 2007 under the name of Cadman Resources Inc., a capital pool Company as defined in the policies of the TSX Venture Exchange (the "Exchange"). In December 2010 the Company was transferred to the NEX Board. In July 2012, the Company listed on the Canadian Stock Exchange ("CSE") and voluntarily delisted from the NEX Board.

In April 2014, the Company changed name to Matica Graphite Inc. and traded under the symbol GRF. In July 2014, the Company changed name to Matica Enterprises Inc. and the Company's shares were also accepted for trading on the Frankfurt Stock Exchange. The Company then completed a change of business with a primary focus in the life sciences focused on the medical marijuana industry and in November 2014 the shares resumed trading on the CSE under the new symbol MMJ.

The executive offices of the Company are at Suite 1102, 44 Victoria Street, Toronto, ON M5C 1Y2, Canada.

The Company no longer holds any mineral property titles, however, it continues to hold a royalty interest in a Nevada lithium property. The business of exploring for minerals involved a high degree of risk and there could be no assurances that exploration programs would result in profitable operations. The recoverability of the carrying value of exploration and evaluation assets and the Company's continued existence was dependent upon the preservation of its interest in the underlying properties, the discovery of economically recoverable minerals, the achievement of profitable operations, or the ability of the Company to raise alternative financing, if necessary, or alternatively upon the Company's ability to dispose of its interests on an advantageous basis.

Although the Company had taken steps to verify title to the properties on which it was conducting exploration and in which it had an interest, in accordance with industry standards for the current stage of exploration of such properties, these procedures did not guarantee the Company's title. Property title may be subject to unregistered prior agreements, social licensing requirements, and non-compliance with regulatory requirements. The Company's assets could also have been subject to increases in taxes and royalties, renegotiation of contracts, and political and social uncertainty.

The Company has a net loss of \$3,171,548 for the nine months ended September 30, 2018 (2017 - \$337,631), an accumulated deficit of \$14,077,824 (December 31, 2017 - \$11,760,241) and working capital of \$8,810,129 (December 31, 2017 - 4,672,392) which has been funded primarily by the issuance of equity. The Company does not yet generate cash flows from operations and accordingly the Company may need to raise additional funds through future issuance of securities or debt financing (see Note 14). Although the Company has raised funds in the past, there can be no assurance the Company will be able to raise sufficient funds in the future, in which case the Company may be unable to meet its obligations as they come due in the normal course of business. It is not possible to predict whether financing efforts will be successful or if the Company will ever attain a profitable level of operations.

The Company's ability to continue as a going concern is uncertain and is dependent upon developing a Health Canada approved facility for growing and selling medical marijuana and maintaining continued support from its shareholders and creditors. The outcome of these matters cannot be predicted at this time and in the event that they do not occur, the carrying value of the Company's assets may be adversely affected.

These unaudited condensed consolidated interim financial statements have been prepared with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a forced liquidation. These condensed consolidated interim financial statements do not give effect to adjustments that would be necessary to the carrying amounts and classifications of assets and liabilities should the Company be unable to continue as a going concern. Such adjustments could be material.

2. BASIS OF PRESENTATION

(a) Statement of compliance

These condensed consolidated interim financial statements, including comparatives, have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

These condensed consolidated interim financial statements were approved and authorized for issuance by the Company's Board of Directors on November 28, 2018.

(b) Basis of preparation

The condensed consolidated interim financial statements of the Company have been prepared on an accrual basis except for cash flow information and are based on historical costs, modified for specific financial instruments carried at fair value where applicable. The condensed consolidated interim financial statements are presented in Canadian dollars.

(c) Consolidation

These condensed consolidated interim financial statements for the nine months ended September 30, 2018 and 2017 include the accounts of Matica, its 100% wholly owned subsidiaries Ravenline Exploration Ltd. ("Ravenline"); Nevada subsidiary Ravenline USA Ltd. ("Ravenline USA"); 1022607 B.C. Ltd.; 1022608 B.C. Ltd.; and 1024250 B.C. Ltd. The Company previously held mineral claims to Nevada properties through Ravenline USA.

The three British Columbia numbered subsidiaries were formed to accomplish an arrangement which was terminated in August 2015 under which assets would have been transferred to four subsidiaries, and shares of the subsidiaries would have been distributed to the Company's shareholders. These three numbered subsidiaries were inactive and were dissolved in November 2017.

Subsidiaries consist of entities over which the Company is exposed to, or has rights to, variable returns as well as the ability to affect those returns through the power to direct the relevant activities of the entity. Subsidiaries are fully consolidated from the date control is transferred to the Company and are de-consolidated from the date control ceases. The consolidated financial statements include all the assets, liabilities, revenues, expenses and cash flows of the Company and its subsidiaries after eliminating inter-entity balances and transactions.

3. SIGNIFICANT ACCOUNTING POLICIES

These unaudited condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting ("IAS 34"). They do not include all of the information required for full IFRS annual financial statements.

Please refer to the December 31, 2017 audited financial statements and accompanying notes for a description of the significant accounting policies used by the Company. The policies set out in the Company's December 31, 2017 financial statements were consistently applied to all periods presented unless otherwise noted below. These condensed consolidated interim financial statements should be read in conjunction with the financial statements for the year ended December 31, 2017.

The policies applied in these condensed consolidated interim financial statements are based on IFRS issued and effective as of September 30, 2018. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the year ended December 31, 2018 could result in restatement of these interim consolidated financial statements.

- 3. SIGNIFICANT ACCOUNTING POLICIES (continued)
- (a) Significant accounting judgments, estimates and assumptions

The preparation of the Company's consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities and contingent liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. However, actual outcomes can differ from those estimates.

The areas which require management to make significant estimates and assumptions in determining carrying values include, but are not limited to:

Fair value of investments in securities not quoted in an active market or private company investments. Where the fair values of financial assets recorded on the consolidated statements of financial position cannot be derived from active markets, they are determined using a variety of valuation techniques. The inputs to these models are derived from observable market data where possible, but where observable market data are not available, management's judgment is required to establish fair values.

Decommissioning Liabilities

The Company's provision for decommissioning liabilities represents management's best estimate of the present value of the future cash outflows required to settle estimated reclamation and closure costs at the end of an asset's life. The provision reflects estimates of future costs, inflation, movements in foreign exchange rates and assumptions of risks associated with the future cash outflows, and the applicable risk free interest rates for discounting the future cash outflows. Changes in the above factors can result in a change to the provision recognized by the Company.

Share-Based Payments

Management uses valuation techniques in estimating the fair value of share options granted. The fair value is determined using the Black-Scholes option pricing model which requires management to make certain estimates, judgements, and assumptions in relation to the expected life of the share options, expected volatility, expected risk-free rate, and expected forfeiture rate. Changes to these assumptions could have a material impact on the Company's consolidated financial statements.

Contingencies

The Company estimates the amount of contingencies due to the non-compliance of the expenditure obligation on the flow-through shares issued. Consequently, the Company is subject to the interest and penalties from Canada Revenue Agency. In addition, the Company estimates the costs of indemnification from flow-through share subscribers for taxes and penalties that may arise from their personal tax returns as a result of the Company not meeting its renounciation obligations.

Critical accounting judgements are accounting policies that have been identified as being complex or involving subjective judgements or assessments with a significant risk of material adjustment in the next year.

(Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

Income, Value Added, Withholding and Other Taxes

The Company is subject to income, value added, withholding and other taxes. Significant judgment is required in determining the Company's provisions for taxes. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. The Company recognizes liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. The determination of the Company's income, value added, withholding and other tax liabilities requires interpretation of complex laws and regulations. The Company's interpretation of taxation law as applied to transactions and activities may not coincide with the interpretation of the tax authorities. All tax related filings are subject to government audit and potential reassessment subsequent to the financial statement reporting period. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the tax related accruals and deferred income tax provisions in the period in which such determination is made.

Going Concern

The assessment of the Company's ability to execute its strategy by funding future working capital requirements involves judgement. Management monitors future cash requirements to assess the Company's ability to meet these future funding requirements. Further information regarding going concern is outlined in Note 1.

(b) Adoption of new pronouncements

In 2017, the Company had adopted a number of new IFRS standards, interpretations, amendments and improvements of existing standards. These included IAS 7, IAS 12 and IAS 28. These new standards and changes did not have any material impact on the Company's consolidated financial statements.

(c) New standards and interpretations not yet adopted

Certain new standards, interpretations and amendments to existing standards have been issued by the IASB that are mandatory for future accounting periods. Some updates that are not applicable or are not consequential to the Company may have been excluded from the list below.

The following standards will be effective for annual periods beginning on or after January 1, 2018:

IFRS 9 Financial Instruments - IFRS 9 was issued in November 2009 and contained requirements for financial assets. This standard addresses classification and measurement of financial assets and replaces the multiple category and measurement models in IAS 39 for debt instruments with a new mixed measurement model having only two categories: Amortized cost and fair value through profit or loss. IFRS 9 also replaces the models for measuring equity instruments and such instruments are either recognized at the fair value through profit or loss or at fair value through other comprehensive income. Where such equity instruments are measured at fair value through other comprehensive income, dividends are recognized in profit or loss to the extent not clearly representing a return of investment; however, others gains and losses (including impairments) associated with such instruments remain in accumulated other comprehensive income indefinitely.

Requirements for financial liabilities were added in October 2010 and they largely carried forward existing requirements in IAS 39, *Financial Instruments – Recognition and Measurement*, except that fair value changes due to credit risk for liabilities designated at fair value through profit and loss would generally be recorded in other comprehensive income.

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

IFRS 9 is effective for annual periods beginning on or after January 1, 2018.

IFRS 10 Consolidated Financial Statements ("IFRS 10") and IAS 28 Investments in Associates and Joint Ventures ("IAS 28") - IFRS 10 and IAS 28 were amended in September 2014 to address a conflict between the requirements of IAS 28 and IFRS 10 and clarify that in a transaction involving an associate or joint venture, the extent of gain or loss recognition depends on whether the assets sold or contributed constitute a business. The effective date of these amendments is yet to be determined, however early adoption is permitted.

IFRS 16 - Leases ("IFRS 16") was issued in January 2016 and replaces IAS 17 - Leases as well as some lease related interpretations. With certain exceptions for leases under twelve months in length or for assets of low value, IFRS 16 states that upon lease commencement a lessee recognises a right-of-use asset and a lease liability. The right-of-use asset is initially measured at the amount of the liability plus any initial direct costs. After lease commencement, the lessee shall measure the right-of-use asset at cost less accumulated depreciation and accumulated impairment. A lessee shall either apply IFRS 16 with full retrospective effect or alternatively not restate comparative information but recognise the cumulative effect of initially applying IFRS 16 as an adjustment to opening equity at the date of initial application. IFRS 16 requires that lessors classify each lease as an operating lease or a finance lease. A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership of an underlying asset. Otherwise it is an operating lease. IFRS 16 is effective for annual periods beginning on or after January 1, 2019. Earlier adoption is permitted if IFRS 15 has also been applied.

IFRIC 23 – Uncertainty Over Income Tax Treatments ("IFRIC 23") was issued in June 2017 and clarifies the accounting for uncertainties in income taxes. The interpretation committee concluded that an entity shall consider whether it is probable that a taxation authority will accept an uncertain tax treatment. If an entity concludes it is probable that the taxation authority will accept an uncertain tax treatment, then the entity shall determine taxable profit (tax loss), tax bases, unused tax losses and credits or tax rates consistently with the tax treatment used or planned to be used in its income tax filings. If an entity concludes it is not probable that the taxation authority will accept an uncertain tax treatment, the entity shall reflect the effect of uncertainty in determining the related taxable profit (tax loss), tax bases, unused tax losses and credits or tax rates. IFRIC 23 is effective for annual periods beginning on or after January 1, 2019. Earlier adoption is permitted.

The Company has not yet begun the process of assessing the impact that the new and amended standards will have on its consolidated financial statements or whether to early adopt any of the new requirements.

4. MARKETABLE SECURITIES

In July 2016, the Company received 4,700,000 common shares of Spearmint Resources Inc. valued at \$188,000 based on a quoted market price of \$0.04 per share for the sale of the Clayton Valley properties (see Note 6). During 2017, the Company sold all 4,700,000 common shares for proceeds of \$121,600 net of commissions and realized a gain of \$27,600.

In May 2017, the Company received 350,000 common shares of Cultivator Catalyst Corp. ("CCC"), a private company, at a deemed value of \$350,000 based upon a \$1.00 per share financing completed by CCC. This represented 50% of the agreed to \$700,000 third party settlement of the Company's legal claims against THC Dispensaries Canada Inc. ("THCD"). In December 2017, an additional 175,000 shares of CCC were received at a deemed value of \$350,000 based upon a \$2.00 per share financing completed by CCC in December 2017. The value of these 525,000 shares was adjusted to \$2,625,000 at September 30, 2018 to reflect the September 2018 private placements at \$5.00 per share as reported by CCC on SEDAR. See Subsequent Events Note 14.

5. OTHER INVESTMENTS

(a) Yunify Natural Technologies

In March 2018, the Company signed a definitive agreement with Yunify Natural Technologies ("Yunify"), a Quebec based health and personal care research and innovation technology company. The Company has subscribed for a \$2,000,000 (\$600,000 paid on signing) convertible debenture bearing interest at six percent per annum. The next \$400,000 is due upon the removal of the halt on the target shell company and the final \$1,000,000 is due upon Yunify becoming listed and trading. The debenture is convertible into units of Yunify at a \$0.225 exercise price. Each unit will be comprised of one common share, one-half of one common share purchase warrant of which one full warrant will entitle the holder to purchase one common share of Yunify for a period of 36 months from the closing date at an exercise price of \$0.35 per warrant, and one-half common share of the Company for a period of 36 months from the closing date at an exercise price of \$0.50 per warrant. By fully exercising the warrants, the Company may acquire up to a 40 per cent interest in Yunify.

(b) RoyalMax Biotechnology Canada Inc.

In March 2017, the Company signed a letter of intent ("LOI") with RoyalMax Biotechnology Canada Inc. "RoyalMax", an arms length applicant under the Access to Cannabis for Medical Purposes Regulation ("ACMPR"). Pursuant to the agreement, the \$50,000 due on signing the LOI was paid and an additional \$135,000 was paid on signing a definitive agreement in April 2017. The Company issued 6,000,000 common shares (fair value on date of issue at \$270,000) upon receipt of due diligence disclosure materials. The Company may earn a 65% interest in RoyalMax for funding a cumulative minimum amount of \$2,200,000 for the build out of a medical marijuana growing facility up to and including receiving a licence from Health Canada. The Company may receive an additional 5% interest for making a payment of \$400,000 within 30 days of notification of licensing by Health Canada. A final payment of \$400,000 will become due after twelve months of production at the facility.

	RoyalMax, Quebec \$
Balance, December 31, 2016	-
Acquisition costs	455,000
Funding of facility build out	3,350,064
Balance, December 31, 2017	3,805,064
Funding of facility build out	1,872,906
Balance, September 30, 2018	5,677,970

As at September 30, 2018, the Dorval facility had not yet received a cultivation licence from Health Canada and therefore the Company had not yet earned the initial 65% interest in RoyalMax.

(c) Secured loan to 93802601 Quebec Inc.

In June 2018, the Company made available to a private Quebec corporation a \$1,500,000 revolving line of credit secured by a mortgage against a 181-acre agricultural property purchased by the Quebec corporation using line of credit funds. The loan accrues interest at 2% per annum. The proceeds of the line of credit are to be used to develop the agricultural property.

(Expressed in Canadian Dollars)

5. OTHER INVESTMENTS (continued)

The two shareholders of the Quebec corporation are related to Matica's director and interim CFO. Both shareholders are residents of Quebec which is a requirement to purchase agricultural land. Matica's director and CEO was appointed a director and secretary of the Quebec corporation to represent the interests of Matica in the development of the property.

(d) Unsecured loan to Capital NX Phase Inc.

In September 2018, the Company made a \$100,000 unsecured loan to Capital NX Phase Inc. ("Capital NX"), a Quebec company which is expected to transition into the listed trading facility for Yunify. The loan bears interest at 12% per annum with a provision to increase retroactively to 18% if the halt on Capital NX is not removed within 90 days of the loan.

6. EXPLORATION AND EVALUATION ASSETS

Clayton Valley, Nevada

In February 2016, the Company acquired a lithium property in the Clayton Valley, Nevada. The property was subject to a 3.75% net smelter return ("NSR"). In July 2016, the Company agreed to sell the Clayton Valley properties to Spearmint Resources Inc. ("Spearmint") for 4,700,000 common shares of Spearmint issued in July 2016. As a result of the sale, the Company wrote off the remaining carrying value of the property. The Company continues to hold a 2% NSR on one of the properties. Spearmint may purchase half of the 2% NSR for US\$500,000.

7. SHARE CAPITAL

(a) Authorized

An unlimited number of common shares without par value.

(b) Issued and outstanding

Shares issued for the year ended December 31, 2017:

In January 2017, the Company issued 4,600,000 common shares to two directors and officers in lieu of \$69,000 of their 2017 compensation (based on the quoted market price on the date of issuance). The Company also issued 200,000 common shares to a service provider as settlement of \$5,691 of debt.

In May 2017, the Company issued 2,142,857 common shares to three directors and/or officers in lieu of their remaining \$75,000 of 2017 compensation. The Company also issued 857,143 common shares to a service provider valued at \$30,000 (based on the quoted market price on the date of issuance).

In July 2017, the Company closed a private placement of 50,466,000 units at \$0.05 for gross proceeds of \$2,523,300. Each unit consists of a common share and a share purchase warrant exercisable at \$0.10 for 18 months following the closing date. The Company issued 1,356,960 broker share purchase warrants exercisable at \$0.05 for 18 months from the closing date and paid \$134,864 in finders fees.

For the year ended December 31, 2017, 21,439,500 common shares were issued on exercise of warrants for cash proceeds of \$2,375,725.

7. SHARE CAPITAL (continued)

For the year ended December 31, 2017, 39,900,000 common shares were issued on exercise of stock options for cash proceeds of \$2,655,500.

Shares issued for the nine months ended September 30, 2018:

For the nine months ended September 30, 2018, 21,435,667 common shares were issued on exercise of warrants for cash proceeds of \$2,400,386.

For the nine months ended September 30, 2018, 6,800,000 common shares were issued on exercise of stock options for cash proceeds of \$2,892,000.

In January 2018, the Company issued 171,429 common shares (valued at \$72,000) to two directors and officers in lieu of a portion of their 2018 compensation. The Company also issued 35,714 common shares to a service provider as settlement of \$15,000 of debt (based on the quoted market price on the date of issuance).

In April 2018, the Company closed a private placement for 1,500,000 units at \$0.35 for gross proceeds of \$525,000. Each unit consists of a common share and a share purchase warrant exercisable at \$0.45 for two years following the closing date. The Company issued an additional 120,000 units in finders fees.

In May 2018, the Company issued 290,908 common shares (valued at \$64,000) to two directors and officers in lieu of their remaining 2018 compensation. The Company also issued 150,000 common shares to a service provider as settlement of \$33,000 of debt (based on the quoted market price on the date of issuance).

(c) Share purchase warrants

A summary of the changes in the Company's warrants for the nine months ended September 30, 2018 is presented below:

	Number of warrants	Weighted average exercise price
		\$
Balance, December 31, 2016	25,866,025	0.11
Issued	51,822,960	0.10
Exercised	(21,439,500)	(0.11)
Expired or cancelled	(11,120,750)	(0.06)
Balance, December 31, 2017	45,128,735	0.11
Issued	1,620,000	0.45
Exercised	(21,435,667)	(0.11)
Expired or cancelled	(74,000)	(0.15)
Balance, September 30, 2018	25,239,068	0.12

In January 2017, 7,270,000 warrants exercisable at \$0.07 expired unexercised.

In April 2017, 3,850,750 warrants exercisable at \$0.05 expired unexercised.

In July 2017, 50,466,000 warrants exercisable at \$0.10 and 1,356,960 broker warrants exercisable at \$0.05 were issued in relation to a private placement. These warrants expire after 18 months in January 2019. See Note 7(b).

(Expressed in Canadian Dollars)

7. SHARE CAPITAL (continued)

In March 2018, 74,000 warrants exercisable at \$0.15 expired unexercised.

The following table summarizes the share purchase warrants outstanding and exercisable as at September 30, 2018:

Exercise price	Expiry date	Number of warrants
\$ 0.10	01/10/2019*	23,261,500
\$ 0.05	01/10/2019*	357,568
\$ 0.45	04/11/2020	1,620,000
		25.239.068

^{*}See Subsequent Events Note 14

As at September 30, 2018, 25,239,068 warrants (2017 - 64,668,235 warrants) with a weighted average remaining contractual life of 0.36 years (2017 - 1.11 years) were outstanding and exercisable, entitling the holders thereof the right to purchase one common share for each whole warrant held.

(d) Stock options

The Company has an incentive share option plan for granting options to directors, employees and consultants, under which the total outstanding options are limited to 10% of the outstanding common shares of the Company at any one time. Under the plan, the exercise price of an option shall not be less than the market price at the time of granting, or as permitted by the policies of the Exchange.

Options granted are non-transferable and may not exceed a term of five years from the grant date. Vesting is as determined by the directors at the time of grant.

A summary of the changes in the Company's stock options for the nine months ended September 30, 2018 is presented below:

	Number of	Weighted average
	options	exercise price
		\$
Balance, December 31, 2016	11,325,000	0.025
Options granted	47,050,000	0.17
Options exercised	(39,900,000)	(0.07)
Options cancelled or expired	(225,000)	(0.05)
Balance, December 31, 2017	18,250,000	0.30
Options granted	22,450,000	0.31
Options exercised	(6,800,000)	(0.43)
Options cancelled or expired	(5,850,000)	(0.38)
Balance, September 30, 2018	28,050,000	0.26

In February 2017, the Company granted 6,000,000 stock options to three consultants. The options were exercisable at a price of \$0.03 per share for a period of six months expiring in August 2017.

In March 2017, the Company granted 4,500,000 stock options to three consultants. The options were exercisable at a price of \$0.045 per share for a period of six months expiring in September 2017.

7. SHARE CAPITAL (continued)

In March 2017, the Company granted 1,800,000 stock options to two directors and two consultants. The options are exercisable at a price of \$0.045 per share for a period of two years expiring in March 2019.

In March 2017, the Company granted 500,000 stock options to a consultant. The options are exercisable at a price of \$0.045 per share for a period of 2.5 years expiring in September 2019.

In July 2017, the Company granted 10,000,000 stock options to four directors and two consultants of the Company. The options are exercisable at a price of \$0.11 per share for a period of two years expiring in July 2019.

In July 2017, the Company granted 4,500,000 stock options to three consultants. The options were exercisable at a price of \$0.11 per share for a period of six months expiring in January 2018.

In August 2017, the Company granted 2,000,000 stock options to a consultant. The options were exercisable at a price of \$0.10 per share for a period of six months expiring in February 2018.

In November 2017, the Company granted 2,000,000 stock options to a consultant. The options were exercisable at a price of \$0.095 per share for a period of five months expiring in April 2018.

In November 2017, the Company granted 4,500,000 stock options to three consultants. The options were exercisable at a price of \$0.16 per share for a period of five months expiring in April 2018.

In November 2017, the Company granted 250,000 stock options to a consultant. The options are exercisable at a price of \$0.16 per share for a period three years expiring in November 2020.

In December 2017, the Company granted 4,000,000 stock options to two consultants. The options were exercisable at a price of \$0.42 per share for a period of six months expiring in June 2018.

In December 2017, the Company granted 7,000,000 stock options to four directors and one consultant. The options are exercisable at a price of \$0.42 per share for a period of three years expiring in December 2020.

In January 2018, the Company granted 2,500,000 stock options to two consulting companies. The options were exercisable at a price of \$0.58 for a period of six months expiring on July 8, 2018.

In February 2018, the Company granted 4,000,000 stock options to two consulting companies. The options were exercisable at a price of \$0.32 per share for a period of six months expiring on August 3, 2018.

In March 2018, the Company granted 7,750,000 stock options to four directors and/or officers, two consultants and a consulting company. The options are exercisable at \$0.35 of which 7,250,000 expire on March 23, 2021, and 500,000 expiring on September 23, 2018.

In August 2018, the Company granted 8,200,000 stock options to four directors and/or officers and five consultants. The options are exercisable at \$0.175 of which 7,000,000 expire on August 23, 2021, and 1,200,000 expire on January 23, 2019.

All options granted above vested immediately on the date of grant.

The weighted average grant date fair value of stock options granted during the nine months ended September 30, 2018 was \$0.185 (2017 - \$0.043).

7. SHARE CAPITAL (continued)

Expected volatility

Expected life

For purposes of the calculation, the following assumptions were used under the Black-Scholes model:

	August 23,	August 23,	March 23,	March 23,	February 3,
Issue date	2018	2018	2018	2018	2018
Share price	\$0.175	\$0.175	\$0.35	\$0.35	\$0.32
Risk free interest rate	2.16%	2.14%	1.92%	1.80%	1.85%
Expected dividend yield	0%	0%	0%	0%	0%
Expected volatility	140%	140%	140%	140%	140%
Expected life	3 years	0.5 years	3 years	0.5 years	0.5 years
	January 5,	December 22,	December 22,	November 24,	November 24,
Issue date	2018	2017	2017	2017	2017
Share price	\$0.58	\$0.42	\$0.42	\$0.16	\$0.16
Risk free interest rate	1.73%	1.71%	1.66%	1.48%	1.41%
Expected dividend yield	0%	0%	0%	0%	0%
Expected volatility	140%	142%	140%	166%	175%
Expected life	0.5 years	3 years	0.5 years	3 years	0.42 years
	November 24,	August 11,	July 11,	July 11,	March 15,
Issue date	2017	2017	2017	2017	2017
Share price	\$0.095	\$0.10	\$0.11	\$0.11	\$0.045
Risk free interest rate	1.44%	1.23%	1.19%	1.19%	0.80%
Expected dividend yield	0%	0%	0%	0%	0%
Expected volatility	121%	166%	164%	135%	130%
Expected life	0.42 years	0.5 years	0.5 years	2 years	2.5 years
	March 15,	March 15,	February 27,	February 24,	
Issue date	2017	2017	2017	2017	
Share price	\$0.045	\$0.045	\$0.03	\$0.03	
Risk free interest rate	0.80%	0.80%	0.76%	0.76%	
Expected dividend yield	0%	0%	0%	0%	
Francisco de la contratilita de	4000/	40.40/	4000/	0440/	

The following table summarizes the options outstanding and exercisable as at September 30, 2018:

134%

0.5 years

163%

0.5 years

211%

0.5 years

130%

2 years

Exercise price	Expiry date	Number of options
\$ 0.11	07/11/2019	6,500,000
\$ 0.16	11/24/2020	100,000
\$ 0.42	12/24/2020	6,000,000
\$ 0.35	03/23/2021	7,250,000
\$ 0.175	01/23/2019	1,200,000
\$ 0.175	08/23/2021	7,000,000
		28,050,000

^{*}See Subsequent Events Note 14

As at September 30, 2018, 28,050,000 options (2017 - 17,500,000) with a weighted average remaining contractual life of 2.04 years (2017 - 1.35 years) were outstanding and exercisable, entitling the holders thereof the right to purchase one common share for each option held.

(Expressed in Canadian Dollars)

8. RELATED PARTY TRANSACTIONS

The following is a summary of transactions with directors and officers, and companies controlled by directors of the Company:

Due to related parties comprised amounts owed to directors and officers as at September 30, 2018 of \$9,037 (December 31, 2017 - \$13,719). These amounts are unsecured, due on demand and non-interest bearing.

During the year ended December 31, 2017, the Company issued 6,742,857 common shares valued at \$144,000 to three directors and/or officers in lieu of their 2017 compensation.

During the nine months ended September 30, 2018, the Company issued 462,337 common shares valued at \$136,000 to two directors and/or officers in lieu of their 2018 compensation.

Key Management Compensation:

The Company has identified its directors and senior officers as its key management personnel. No postemployment benefits, other long-terms benefits and termination benefits were made during the nine months ended September 30, 2018 and 2017. Short-term key management compensation for the nine months ended September 30, 2018 and 2017 are as follow:

	2018	2017
	\$	\$
Director fees	9,000	4,500
Management fees, paid to officers and directors	108,000	105,000
Share-based compensation to officers and directors	2,460,828	576,706
Total key management compensation	2,577,828	686,206

9. MANAGEMENT OF CAPITAL

The Company's objective for capital management is to safeguard its ability to support the Company's normal operating requirement on an ongoing basis and continue the development its evaluation assets.

The Company seeks to manage capital to provide adequate funding for its projects while minimizing dilution for its existing shareholders. As the Company has no practical ability presently to raise money by long term or other debt, for practical purposes, all of its capital management is directed towards management of its equity, warrant and option issuances. There is thus very limited flexibility in its capital management. The Company is not subject to any externally imposed capital requirements.

10. FINANCIAL INSTRUMENTS AND RISK

Classification

Financial instruments are classified into one of five categories: fair value through profit or loss ("FVTPL"), held-to-maturity, loans and receivables, available-for-sale financial assets or other financial liabilities. All financial instruments are measured at fair value except for loans and receivables, held-to-maturity investments and other financial liabilities which are measured at amortized cost. Subsequent measurement and accounting for changes in the values of these investments will depend on their initial classification as follows: FVTPL financial assets are measured at fair value with changes in fair value recognized in operations. Available-for-sale financial instruments are measured at fair value with changes in fair value recorded in other comprehensive income until the change in value is realized or the instrument is derecognized or permanently impaired.

(Expressed in Canadian Dollars)

10. FINANCIAL INSTRUMENTS AND RISK (continued)

The Company has classified its cash and cash equivalents, and marketable securities as FVTPL. Accounts payable and accrued liabilities, note payable and due to related parties are classified as other financial liabilities.

The following table summarizes the carrying values of the Company's financial instruments:

	September 30,	December 31,
	2018	2017
	\$	\$
FVTPL (i)	8,343,535	4,863,666
Other financial liabilities (ii)	55,787	78,948

- (i) Cash and cash equivalents, and marketable securities
- (ii) Accounts payable and accrued liabilities, note payable and due to related parties

Fair value

As at September 30, 2018, the Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts payable and accrued liabilities, note payable and due to related parties. The fair values of these financial instruments approximate their carrying values because of their current nature.

The Company's financial instruments measured at fair value on a recurring basis at are as follows:

At September 30, 2018:

	Level 1	Level 2	Level 3	Total
	\$	\$	\$	\$
Cash and cash equivalents	5,718,535	-	-	5,718,535
Marketable securities	-	-	2,625,000	2,625,000
At December 31, 2017:				
	Level 1	Level 2	Level 3	Total
	\$	\$	\$	\$
Cash and cash equivalents	3,813,666	-	-	3,813,666
Marketable securities	-	-	1,050,000	1,050,000

Financial instruments classified as Level 3 are measured at fair value utilizing non-observable market inputs. The net realized gains (losses) and net change in unrealized gains (losses) are recognized in the consolidated statements of loss.

Within Level 3, the Company included private company investments which are not quoted on a recognized securities exchange. The key assumptions used in the valuation of these instruments include, but are not limited to, the value at which a recent financing was done by the investee, company-specific information, trends in general market conditions and the share performance of comparable publicly-traded companies.

The following table presents the fair value, categorized by key valuation techniques and the unobservable inputs used within Level 3 of the fair value hierarchy:

10. FINANCIAL INSTRUMENTS AND RISK (continued)

For those investments valued based on recent financings, management has determined that there are no reasonably possible alternative assumptions that would change the fair value significantly as at September 30, 2018. A 10% change in the fair value of these investments would result in a corresponding +/- \$262,500 change to the fair value of the investments.

The sensitivity analysis is intended to reflect the uncertainty inherent in the valuation of these investments under current market conditions, and its results cannot be extrapolated due to non-linear effects that changes in valuation assumptions may have on the fair value of these investments. Furthermore, the analysis does not indicate a probability of such changes occurring and it does not necessarily represent the Company's view of expected future changes in the fair value of these investments.

Credit risk

Financial instruments that potentially subject the Company to concentrations of credit risks consist principally of cash. To minimize the credit risk on cash the Company places the instrument with a financial institution.

Liquidity risk

The Company ensures its holding of cash is sufficient to meet its short-term general and administrative expenditures. All of the Company's financial liabilities have contractual maturities of 30 days or less or are due on demand and are subject to normal trade terms. The Company does not have investments in any asset backed commercial paper or similar instruments.

Foreign exchange risk

The Company has minimal foreign exchange risk as most of its transactions are in Canadian dollars. Foreign currency transactions are recorded in Canadian dollars based on exchange rates as at the time of the transaction.

Interest rate risk

The Company manages its interest rate risk by obtaining the best commercial deposit interest rates available in the market by the major Canadian financial institutions. The Company does not have any non-fixed rate debt.

11. CONTINGENCIES

On December 22, 2012, the Company closed a non-brokered private placement of 2,003,333 flow-through units at a price of \$0.06 per unit for gross proceeds of \$120,200. The Company was committed to incur on or before December 31, 2013 a total of \$43,200 of qualifying Canadian Exploration Expenses ("CEE") as described in the Income Tax Act of Canada. As at September 30, 2018, the Company had unfulfilled CEE obligations of \$42,770 (2017 - \$42,770). As the Company did not fulfill the expenditure obligation, the Company has accrued \$31,947 as at September 30, 2018 (2017 - \$26,947) related to Part XII.6 tax and related penalties and interests on the unfulfilled commitments. Furthermore, the Company may also have to indemnify shareholders for taxes and related amounts in respect of the unspent portion of the commitment. As at September 30, 2018, an estimated amount accrued relating to the indemnification on the unfulfilled commitments totalled \$85,277 (2017 - \$85,277). The outcome of the amount of actual claims and penalties, if any, is contingent on assessments by the Canada Revenue Agency and any subsequent claims by subscribers against the Company.

11. CONTINGENCIES (continued)

The Company may become party to legal proceedings and other claims in the ordinary course of its operations. Litigation and other claims are subject to many uncertainties and the outcome of individual matters is not predictable. Where management can estimate that there is a loss probable, a provision is recorded in the consolidated financial statements. Where proceedings are at a premature stage or the ultimate outcome is not determinable, then no provision is recorded. It is possible that the final resolution of any such matters may require the Company to make expenditures over an extended period of time and in a range of amounts that cannot be reasonably estimated and may differ significantly from any amounts recorded in these consolidated financial statements. Should the Company be unsuccessful in its defense or settlement of one or more of legal actions or other claims, there could be a materially adverse effect on the Company's financial position, future expectations, and cash flows.

12. COMMITMENTS

The Company entered into a rental agreement for its office space in Toronto for the period from November 1, 2014 to January 31, 2020. The remaining rental commitment is \$15,390 for 2018, \$61,558 for 2019, and \$5,130 for 2020.

13. SEGMENT DISCLOSURE

Geographic Information

The Company's assets at September 30, 2018 and 2017 were based solely in Canada.

Operating segments

During the nine months ended September 30, 2018, the Company operates in the health related sector and is investing in an ACMPR applicant in Quebec, Canada (see Note 5). The Company continues to hold a royalty on a Nevada Lithium property carried at nil value as at September 30, 2018 (see Note 6).

14. SUBSEQUENT EVENTS

- a) Subsequent to September 30, 2018, 1,090,000 warrants were exercised for proceeds of \$109,000.
- b) Subsequent to September 30, 2018, the Company closed a private placement for 4,000,000 units at \$0.125 for gross proceeds of \$500,000. Each unit consists of a common share and a share purchase warrant exercisable at \$0.205 for five years following the closing date.
- c) Subsequent to September 30, 2018, the 525,000 shares of Cultivator Catalyst Corp. were exchanged for 2,625,000 shares of Biome Grow Inc. which became listed and trading on the CSE on October 9, 2018.
- d) Subsequent to September 30, 2018, the Company granted 1,450,000 stock options to two consulting companies. The options are exercisable at a price of \$0.195 per share for a period of seven months expiring in May 2019.